Sub Banner Image

Sarepta’s Week Goes From Bad to Worse on FDA Fears, Outlook Cut

Markets

Angel Adegbesan

·

May 9, 2025

·

Bloomberg

Sarepta Therapeutics Inc. capped its worst week in four years as disappointing earnings and regulatory fears hit the drugmaker’s shares.

More from

Bloomberg

More

Markets

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.